HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nimodipine in subcortical vascular dementia trial.

Abstract
Vascular dementia (VaD) is a heterogeneous pathology currently regarded as the result of a variety of causes. Different types of VaD can be identified according to different criteria. This heterogeneity might be one of the causes of the controversial results observed, up to now, in clinical trials. Recently, the 10th revision of the International Classification of Diseases (ICD-10) explicitly identified subcortical VaD as a well-defined subgroup. Abnormalities of white matter are clearly detectable with computed tomography or magnetic resonance scans. The clinicoradiological association of dementia, blood hypertension, and other vascular risk factors, extensive white matter lesions, and small subcortical infarcts might be considered as a clinical univocal entity. Following the encouraging results of a preliminary pilot study, the above-mentioned criteria were followed to define a population of patients to be enrolled in a double-blind, parallel-groups, placebo-controlled clinical trial with nimodipine, which has been proposed as a drug that can improve cognitive functions in patients with VaD. The paper discusses the protocol design of this ongoing trial and its main entry criteria, with particular emphasis on the definition of the population to be enrolled. Implication for future trials in subcortical VaD are discussed further.
AuthorsR Rossi, D Inzitari, L Pantoni, T del Ser, T Erkinjuntti, A Wallin, C Bianchi, J M Badenas, M Beneke
JournalAlzheimer disease and associated disorders (Alzheimer Dis Assoc Disord) 1999 Oct-Dec Vol. 13 Suppl 3 Pg. S159-65 ISSN: 0893-0341 [Print] United States
PMID10609696 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Calcium Channel Blockers
  • Nimodipine
Topics
  • Aged
  • Aged, 80 and over
  • Calcium Channel Blockers (therapeutic use)
  • Cerebral Cortex (blood supply)
  • Dementia, Vascular (drug therapy)
  • Double-Blind Method
  • Humans
  • International Cooperation
  • Middle Aged
  • Nimodipine (therapeutic use)
  • Research Design

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: